Compare LICN & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LICN | ANIX |
|---|---|---|
| Founded | 2004 | 1982 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 114.0M |
| IPO Year | 2021 | 2013 |
| Metric | LICN | ANIX |
|---|---|---|
| Price | $1.05 | $2.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 13.4K | ★ 320.7K |
| Earning Date | 04-28-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $2.32 |
| 52 Week High | $9.49 | $5.46 |
| Indicator | LICN | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 31.15 |
| Support Level | $0.73 | $2.73 |
| Resistance Level | $1.76 | $3.09 |
| Average True Range (ATR) | 0.09 | 0.22 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 40.48 | 11.55 |
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational, and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and the sales of financial and taxation training software.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.